Display options
Cite
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 2015;10:89-98doi: 10.2147/CE.S82905.
Inomata, M., Nishioka, Y., & Azuma, A. (2015). Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core evidence, 1089-98. https://doi.org/10.2147/CE.S82905
Inomata, Minoru, et al. "Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis." Core evidence vol. 10 (2015): 89-98. doi: https://doi.org/10.2147/CE.S82905
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015. PMID: 26346347; PMCID: PMC4555978.
Copy Download .nbib Format: NLM
Share it on

Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015.

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Core evidence

Minoru Inomata, Yasuhiko Nishioka, Arata Azuma

Affiliations

  1. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo.
  2. Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.

PMID: 26346347 PMCID: PMC4555978 DOI: 10.2147/CE.S82905

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. Other growth factors, including fibroblast growth factor and vascular endothelial growth factor, are also thought to contribute to the pathogenesis of pulmonary fibrosis. Nintedanib is an inhibitor of multiple tyrosine kinases, including receptors for PDGF, fibroblast growth factor, and vascular endothelial growth factor. In the Phase II TOMORROW trial, treatment with 150 mg of nintedanib twice daily showed a trend to slow the decline in lung function and significantly decrease acute exacerbations in patients with IPF, while showing an acceptable safety profile. The Phase III INPULSIS trials demonstrated a significant decrease in the annual rate of decline in forced vital capacity in IPF patients treated with 150 mg nintedanib twice daily. In the INPULSIS-2 trial, the time to the first acute exacerbation significantly increased in IPF patients who were treated with 150 mg of nintedanib twice daily. Pirfenidone, another antifibrotic drug, was shown to limit the decline in pulmonary function in patients with IPF in the ASCEND trial. Combination therapy with nintedanib and pirfenidone is anticipated, although further evaluation of its long-term safety is needed. There is limited evidence for the safety of the combination therapy although a Phase II trial conducted in Japan demonstrated that combination therapy with nintedanib and pirfenidone was tolerable for 1 month. Available antifibrotic agents (ie, pirfenidone and N-acetylcysteine) have limited efficacy as single therapies for IPF; therefore, further study of combination therapy with antifibrotic agents is needed.

Keywords: fibroblast growth factor; forced vital capacity; pirfenidone; platelet-derived growth factor; vascular endothelial growth factor

References

  1. Cell. 1996 Jun 14;85(6):863-73 - PubMed
  2. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2084-9 - PubMed
  3. Am J Respir Cell Mol Biol. 1993 Dec;9(6):637-44 - PubMed
  4. J Clin Invest. 2009 May;119(5):1298-311 - PubMed
  5. Ann Intern Med. 2012 May 15;156(10):684-91 - PubMed
  6. Respir Res. 2013 Jul 13;14:73 - PubMed
  7. Mol Med. 2012 Sep 07;18:992-1002 - PubMed
  8. Eur Respir J. 2010 Mar;35(3):496-504 - PubMed
  9. J Pharmacol Exp Ther. 2014 May;349(2):209-20 - PubMed
  10. N Engl J Med. 2014 May 29;370(22):2083-92 - PubMed
  11. Am J Respir Cell Mol Biol. 1999 May;20(5):1020-7 - PubMed
  12. Am J Respir Crit Care Med. 2003 May 15;167(10):1416-26 - PubMed
  13. Am J Respir Cell Mol Biol. 2015 Jan;52(1):116-28 - PubMed
  14. Proc Natl Acad Sci U S A. 1995 Oct 10;92 (21):9570-4 - PubMed
  15. J Med Chem. 2009 Jul 23;52(14):4466-80 - PubMed
  16. Mol Cell Biochem. 2000 Jan;204(1-2):119-26 - PubMed
  17. Angiogenesis. 2006;9(4):225-30; discussion 231 - PubMed
  18. Ann Intern Med. 2001 Jan 16;134(2):136-51 - PubMed
  19. J Med Invest. 2013;60(3-4):175-83 - PubMed
  20. J Immunol. 2005 Jul 15;175(2):1224-31 - PubMed
  21. Sarcoidosis Vasc Diffuse Lung Dis. 2013 Dec 17;30(4):249-61 - PubMed
  22. Eur J Pharmacol. 2002 Jun 20;446(1-3):167-76 - PubMed
  23. Genes Dev. 1994 Aug 15;8(16):1888-96 - PubMed
  24. Cytokine Growth Factor Rev. 2003 Apr;14(2):91-8 - PubMed
  25. Am J Pathol. 1999 Jul;155(1):213-21 - PubMed
  26. Eur Respir J. 2010 Apr;35(4):821-9 - PubMed
  27. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1279-85 - PubMed
  28. Ther Adv Respir Dis. 2010 Dec;4(6):367-88 - PubMed
  29. Biochem Biophys Res Commun. 1999 Nov 19;265(2):503-8 - PubMed
  30. Am J Physiol. 1999 Feb;276(2 Pt 1):L311-8 - PubMed
  31. Clin Dev Immunol. 2009;2009:537929 - PubMed
  32. Eur J Pharmacol. 2008 Aug 20;590(1-3):400-8 - PubMed
  33. Eur Respir Rev. 2012 Jun 1;21(124):152-60 - PubMed
  34. Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L182-8 - PubMed
  35. Chest. 1996 Mar;109(3):780-6 - PubMed
  36. J Pharmacol Exp Ther. 1999 Oct;291(1):367-73 - PubMed
  37. J Pharmacol Exp Ther. 1999 Apr;289(1):211-8 - PubMed
  38. Eur Respir J. 2015 May;45(5):1382-92 - PubMed
  39. Lancet. 2011 May 21;377(9779):1760-9 - PubMed
  40. N Engl J Med. 2014 May 29;370(22):2071-82 - PubMed
  41. Arch Biochem Biophys. 2001 Nov 1;395(1):103-12 - PubMed
  42. Eur Respir J. 2007 May;29(5):976-85 - PubMed
  43. Respiration. 2011;82(3):273-87 - PubMed
  44. FASEB J. 2013 Nov;27(11):4444-54 - PubMed
  45. Lancet Respir Med. 2013 May;1(3):191-2 - PubMed
  46. Eur Respir J. 2011 Feb;37(2):356-63 - PubMed
  47. N Engl J Med. 2012 May 24;366(21):1968-77 - PubMed
  48. J Clin Invest. 2012 Aug;122(8):2756-62 - PubMed
  49. Nat Rev Cancer. 2010 Feb;10(2):116-29 - PubMed
  50. J Exp Med. 2005 Mar 21;201(6):925-35 - PubMed
  51. Cancer Res. 2008 Jun 15;68(12):4774-82 - PubMed
  52. Arch Intern Med. 2008 Jan 28;168(2):159-66 - PubMed
  53. Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L871-9 - PubMed
  54. J Clin Invest. 2004 Nov;114(9):1308-16 - PubMed
  55. Anat Rec (Hoboken). 2008 Dec;291(12):1649-61 - PubMed
  56. Ann Intern Med. 2014 Oct 21;161(8):JC4-5 - PubMed
  57. PLoS One. 2010 Aug 17;5(8):e12228 - PubMed
  58. Genes Dev. 2008 May 15;22(10):1276-312 - PubMed
  59. Lung. 2005 Jul-Aug;183(4):225-37 - PubMed
  60. Am J Physiol Lung Cell Mol Physiol. 2010 Aug;299(2):L222-31 - PubMed
  61. Int Immunopharmacol. 2009 Jan;9(1):70-9 - PubMed
  62. J Clin Invest. 1990 Oct;86(4):1055-64 - PubMed
  63. Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7 - PubMed
  64. Am J Respir Crit Care Med. 2012 Oct 15;186(8):712-5 - PubMed
  65. Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43 - PubMed
  66. Physiol Rev. 1999 Oct;79(4):1283-316 - PubMed
  67. Nat Rev Drug Discov. 2009 Mar;8(3):235-53 - PubMed
  68. Genes Dev. 1994 Aug 15;8(16):1875-87 - PubMed
  69. Respir Res. 2013 Aug 21;14:86 - PubMed
  70. Development. 1997 Jul;124(14):2691-700 - PubMed
  71. Endocr Relat Cancer. 2000 Sep;7(3):165-97 - PubMed
  72. N Engl J Med. 2011 Sep 22;365(12):1079-87 - PubMed
  73. J Lab Clin Med. 1995 Jun;125(6):779-85 - PubMed
  74. Am J Physiol Lung Cell Mol Physiol. 2000 Dec;279(6):L1038-46 - PubMed
  75. Am J Respir Crit Care Med. 2004 Jun 1;169(11):1203-8 - PubMed
  76. Nat Med. 1996 May;2(5):561-6 - PubMed
  77. J Biol Chem. 2010 Feb 19;285(8):5532-40 - PubMed
  78. N Engl J Med. 2014 May 29;370(22):2142-3 - PubMed
  79. Eur J Pharmacol. 2002 Jun 20;446(1-3):177-85 - PubMed

Publication Types